Efficacy and Economic Evaluation of Nonbiological Artificial Liver Therapy in Acute-on-chronic Hepatitis B Liver Failure

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2023 Jan 16

PMID 36643036

Authors

Cichun Wu

Wenting Peng

Da Cheng

Huimin Gu

Fei Liu

Shifang Peng

Lei Fu

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Nonbiological artificial liver (NBAL) is frequently used as a first-line treatment for hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). This study aimed to compare the therapeutic efficacy and cost-effectiveness ratio (CER) of comprehensive medical treatment, plasma exchange (PE), and double plasma molecular adsorption system (DPMAS) plus half-dose PE (DPMAS+PE) in patients with HBV-ACLF.

Methods: A total of 186 patients with HBV-ACLF randomly received comprehensive medical treatment, PE, or DPMAS+PE and were prospectively evaluated. Patients were divided into four subgroups based on the pretreatment prothrombin activity (PTA): Group I (PTA>40%), group II (PTA 30-40%), group III (PTA 20-30%), and group IV (PTA<20%). The main outcome measures were 28 day effectiveness; 90 day liver transplantation-free survival; change of biochemical parameters; and CER.

Results: DPMAS+PE treatment was associated with significantly higher 28 day effectiveness and 90 day liver transplantation-free survival compared with PE treatment in patients with group I liver failure. Clearance of serum total bilirubin (TBIL), AST, and creatinine (Cr) were significantly higher in the DPMAS+PE group than in the PE group. For subjects with group I liver failure, DPMAS+PE treatment had advantages of lower CER values and better cost-effectiveness.

Conclusions: Compared with comprehensive medical treatment and PE alone, DPMAS with half-dose sequential PE treatment more effectively improved TBIL, AST, and Cr in HBV-ACLF patients, improved 28 day effectiveness and 90 day survival rates in patients with group I liver failure, and was more cost effective. DPMAS+PE is a viable NBAL approach for treatment of HBV-ACLF.

Citing Articles

Association between volume of processed plasma and total bilirubin reduction during plasma adsorption for severe liver disease.

Ma Y, Xu Y, Du L, Bai L, Tang H Eur J Med Res. 2025; 30(1):175.

PMID: 40089798 DOI: 10.1186/s40001-025-02419-4.

A nomogram model based on albumin-bilirubin score for predicting 90-day prognosis in patients with acute-on-chronic liver failure.

Ding W, Shen J, Zhang L, Shao J, Bian Z, Xue H Front Med (Lausanne). 2025; 11():1406275.

PMID: 39835109 PMC: 11744009. DOI: 10.3389/fmed.2024.1406275.

Efficacy and safety of artificial liver support system treatment for immune checkpoint inhibitors related liver failure in patients with hepatocellular carcinoma: Protocol for a randomized controlled clinical trial.

Luo Q, Zhang Y, Li Z, Chen J, Deng Z, Lai J Heliyon. 2024; 10(20):e39095.

PMID: 39640621 PMC: 11620127. DOI: 10.1016/j.heliyon.2024.e39095.

Therapeutic Plasma Exchange in Hepatology: Indications, Techniques, and Practical Application.

Agrawal D, Ariga K, Gupta S, Saigal S J Clin Exp Hepatol. 2024; 15(1):102410.

PMID: 39430641 PMC: 11489060. DOI: 10.1016/j.jceh.2024.102410.

Mixed mode of artificial liver support in patients with acute-on-chronic liver failure: a retrospective cohort study.

Wang X, Peng B, Zhang L, Zhao J, Zhang L, Ren H Hepatol Int. 2023; 17(5):1241-1250.

PMID: 37550499 DOI: 10.1007/s12072-023-10573-2.

References

Sarin S, Choudhury A, Sharma M, Maiwall R, Al Mahtab M, Rahman S . Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019; 13(4):353-390. PMC: 6728300. DOI: 10.1007/s12072-019-09946-3. View

Zhong S, Wang N, Zhao J, Zhang L, Luo L, Zeng W . [Plasma exchange combined with double plasma absorption therapy improve the prognosis of acute-on-chronic liver failure]. Zhonghua Gan Zang Bing Za Zhi. 2018; 26(10):744-749. DOI: 10.3760/cma.j.issn.1007-3418.2018.10.003. View

Keklik M, Sivgin S, Kaynar L, Pala C, Solmaz M, Cetin M . Treatment with plasma exchange may serve benefical effect in patients with severe hyperbilirubinemia: a single center experience. Transfus Apher Sci. 2013; 48(3):323-6. DOI: 10.1016/j.transci.2013.04.009. View

Michalopoulos G, Bhushan B . Liver regeneration: biological and pathological mechanisms and implications. Nat Rev Gastroenterol Hepatol. 2020; 18(1):40-55. DOI: 10.1038/s41575-020-0342-4. View

Winters J . Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematology Am Soc Hematol Educ Program. 2012; 2012:7-12. DOI: 10.1182/asheducation-2012.1.7. View

Li H, Chen L, Zhang N, Li S, Zeng B, Pavesi M . Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B. Sci Rep. 2016; 6:25487. PMC: 4857102. DOI: 10.1038/srep25487. View

Claria J, Stauber R, Coenraad M, Moreau R, Jalan R, Pavesi M . Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatology. 2016; 64(4):1249-64. DOI: 10.1002/hep.28740. View

. [Guideline for diagnosis and treatment of liver failure]. Zhonghua Gan Zang Bing Za Zhi. 2019; 27(1):18-26. DOI: 10.3760/cma.j.issn.1007-3418.2019.01.006. View

Xu W, Li Y, Wang L, Gao H, Chen J, Yuan J . Efficacy and safety of combination treatment of double plasma molecular adsorption system and low volume plasma exchange for patients with hepatitis B virus related acute-on-chronic liver failure: a multicentre randomised controlled clinical trial. BMJ Open. 2021; 11(12):e047690. PMC: 8671914. DOI: 10.1136/bmjopen-2020-047690. View

10.

Wu T, Li J, Shao L, Xin J, Jiang L, Zhou Q . Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut. 2017; 67(12):2181-2191. DOI: 10.1136/gutjnl-2017-314641. View

11.

Arroyo V, Angeli P, Moreau R, Jalan R, Claria J, Trebicka J . The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol. 2020; 74(3):670-685. DOI: 10.1016/j.jhep.2020.11.048. View

12.

Guo X, Wu F, Guo W, Zhang J, Yang Y, Lu Y . Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure. J Int Med Res. 2020; 48(6):300060520932053. PMC: 7303772. DOI: 10.1177/0300060520932053. View

13.

Casulleras M, Zhang I, Lopez-Vicario C, Claria J . Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. Cells. 2020; 9(12). PMC: 7762372. DOI: 10.3390/cells9122632. View

14.

Kong L, Qiu F, Wang H, Shan X, Hu P, Zhong S . [Economic evaluation of plasma exchange combined with dual plasma adsorption therapy for early, mid and late stage liver failure]. Zhonghua Gan Zang Bing Za Zhi. 2020; 28(5):434-440. DOI: 10.3760/cma.j.cn501113-20190122-00025. View

15.

Zhe-Bin W, Ke W, Mo Z, Zhen X, Yu-Bao Z, Ying Y . Early, short-term, low-dose glucocorticoid therapy effectively blocks progression of severe acute exacerbation of chronic hepatitis B to liver failure. Clin Res Hepatol Gastroenterol. 2020; 45(5):101505. DOI: 10.1016/j.clinre.2020.07.010. View

16.

Miyajima A, Tanaka M, Itoh T . Stem/progenitor cells in liver development, homeostasis, regeneration, and reprogramming. Cell Stem Cell. 2014; 14(5):561-74. DOI: 10.1016/j.stem.2014.04.010. View

17.

Inoue K, Watanabe T, Hirasawa H, Yoshiba M . Liver support systems as perioperative care in liver transplantation-historical perspective and recent progress in Japan. Minerva Gastroenterol Dietol. 2010; 56(3):345-53. View

18.

Vaninov N . In the eye of the COVID-19 cytokine storm. Nat Rev Immunol. 2020; 20(5):277. PMC: 7132547. DOI: 10.1038/s41577-020-0305-6. View

19.

Marsden G, Wonderling D . Cost-effectiveness analysis: role and implications. Phlebology. 2013; 28 Suppl 1:135-40. DOI: 10.1177/0268355512475119. View

20.

Yao J, Li S, Zhou L, Luo L, Yuan L, Duan Z . Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure. J Clin Apher. 2019; 34(4):392-398. PMC: 6767528. DOI: 10.1002/jca.21690. View